STAA - STAAR Surgical Company

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
47.95
-0.55 (-1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close48.50
Open48.70
Bid47.70 x 3200
Ask49.00 x 4000
Day's Range47.50 - 49.95
52 Week Range10.75 - 54.00
Volume1,386,712
Avg. Volume507,371
Market Cap2.107B
Beta2.22
PE Ratio (TTM)577.71
EPS (TTM)0.08
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.00
Trade prices are not sourced from all markets
  • Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies
    Zacksyesterday

    Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies

    Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies

  • 5 Stocks With Recent Price Strength to Strengthen Portfolio
    Zacks2 days ago

    5 Stocks With Recent Price Strength to Strengthen Portfolio

    Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

  • Benzinga7 days ago

    The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

    A roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 13.) Abbott Laboratories (NYSE: ABT ) Baxter International Inc ...

  • Business Wire8 days ago

    STAAR Surgical Announces Approval by the FDA of the Visian Toric ICL for the Correction of Myopia with Astigmatism

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that the FDA has granted approval of the PMA Supplement for the Visian Toric ICL for the correction of myopia with astigmatism. This approval represents a meaningful expansion of the Implantable Collamer® Lens (ICL) product line for the correction of refractive error in patients with both myopia and astigmatism which are common conditions in the United States (US).

  • Business Wire9 days ago

    STAAR Surgical Announces EVO ICL Clinical Program for its 15th Annual Surgical Experts Summit in Vienna, Austria, from September 19 – 21, 2018

    STAAR Surgical Company , a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing the EVO ICL Clinical Program which will be presented by Ophthalmic Surgeons to Ophthalmic Surgeons at its invitation only Surgical Experts Summit expected to be attended by over 250 surgeons and invited clinician guests from forty-three countries....

  • Can the Rally in STAAR Surgical (STAA) Shares Continue?
    Zacks16 days ago

    Can the Rally in STAAR Surgical (STAA) Shares Continue?

    STAAR Surgical Company (STAA) has been on the move lately as the stock has risen by 22.7% in the past four weeks, and it is currently trading well above its 20-Day SMA.

  • ACCESSWIRE22 days ago

    Today's Research Reports on Trending Tickers: Glaukos and STAAR Surgical

    NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Wall Street extended gains with the Dow Jones closing at its highest since February, as market participants cheers on a possibility of a trilateral North American ...

  • Los Angeles stocks that are driving Wall Street's latest bull run
    American City Business Journals29 days ago

    Los Angeles stocks that are driving Wall Street's latest bull run

    Beauty product retailer Natural Health Trends Corp. of Rolling Hills was the Los Angeles-area's biggest gainer, rising from 23 cents on March 9, 2009 to $25.90 on Aug. 21 of this year, an increase of 11,160 percent.

  • What Does STAAR Surgical Company’s (NASDAQ:STAA) Ownership Structure Look Like?
    Simply Wall St.29 days ago

    What Does STAAR Surgical Company’s (NASDAQ:STAA) Ownership Structure Look Like?

    In this analysis, my focus will be on developing a perspective on STAAR Surgical Company’s (NASDAQ:STAA) latest ownership structure, a less discussed, but important factor. When it comes to ownershipRead More...

  • Zacks.com highlights: PCM, STAAR Surgical, Verso, Johnson Outdoors and BioSpecifics Technologies
    Zackslast month

    Zacks.com highlights: PCM, STAAR Surgical, Verso, Johnson Outdoors and BioSpecifics Technologies

    Zacks.com highlights: PCM, STAAR Surgical, Verso, Johnson Outdoors and BioSpecifics Technologies

  • 5 Stocks With Recent Price Strength to Enhance Your Returns
    Zackslast month

    5 Stocks With Recent Price Strength to Enhance Your Returns

    Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

  • Business Wirelast month

    STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, and Dr. Maro Kariya of Shinjuku LASIK Clinic in Tokyo, today announced they have entered into a multi-year Strategic Cooperation Agreement to provide STAAR's EVO Visian ICL™ intraocular lenses as a primary and premium option for patients seeking visual freedom from spectacles and contact lenses through refractive eye treatment.

  • Business Wirelast month

    STAAR Surgical Announces Closing of Common Stock Offering

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today the closing of the previously announced underwritten public offering of 1,999,850 shares of its common stock, which includes the full exercise of the underwriter’s option to purchase up to an additional 260,850 shares, at a price to the public of $39.00 per share. The gross proceeds of the offering, before deducting underwriting commissions and offering expenses, were $77,994,150. Canaccord Genuity acted as the sole book-running manager for the offering.

  • Business Wirelast month

    STAAR Surgical Announces Pricing of Public Offering of Common Stock

    STAAR Surgical Company (STAA), a developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today the pricing of the previously announced underwritten public offering of 1,739,000 shares of its common stock, for total gross proceeds of approximately $67,821,000. In addition, STAAR has granted the underwriters of the offering a 30-day option to purchase up to an additional 260,850 shares of its common stock on the same terms and conditions. STAAR intends to use the net proceeds from the offering to fund its operations, which may include advancing and broadening commercialization of its implantable Collamer® lens (ICL) family of products, funding pipeline research and development activities and clinical trials, funding incremental investments in automation and precision manufacturing, and capital expenditures, such as information systems, and for general corporate purposes, including working capital.

  • Business Wirelast month

    STAAR Surgical Announces Public Offering of Common Stock

    STAAR Surgical Company (STAA), a developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today the underwritten public offering of 1,739,000 shares of its common stock. In addition, STAAR has granted the underwriters of the offering a 30-day option to purchase up to an additional 260,850 shares of its common stock on the same terms and conditions. STAAR intends to use the net proceeds from the offering to fund its operations, which may include advancing and broadening commercialization of its implantable Collamer® lens (ICL) family of products, funding pipeline research and development activities and clinical trials, funding incremental investments in automation and precision manufacturing, and capital expenditures, such as information systems, and for general corporate purposes, including working capital.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in BMC Stock, Big 5 Sporting Goods, STAAR Surgical, ABM Industries, Gramercy Property Trust, and Oshkosh — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Aug. 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BMC ...

  • Why STAAR Surgical Company Stock Soared Today
    Motley Fool2 months ago

    Why STAAR Surgical Company Stock Soared Today

    Great Q2 results send STAAR Surgical stock higher.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of STAA earnings conference call or presentation 1-Aug-18 8:30pm GMT

    Q2 2018 STAAR Surgical Co Earnings Call

  • Associated Press2 months ago

    Staar Surgical: 2Q Earnings Snapshot

    On a per-share basis, the Monrovia, California-based company said it had net income of 4 cents. Earnings, adjusted for non-recurring costs, were 9 cents per share. The maker of implantable lenses posted ...

  • Business Wire2 months ago

    STAAR Surgical ICL Sales Up 67%; Company Raises Outlook for 2018

    STAAR Surgical Company , a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended June 29, 2018.

  • ACCESSWIRE2 months ago

    Free Technical Research on IsoRay and Three More Medical Supplies Equities

    On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).

  • Business Wire2 months ago

    STAAR Surgical to Report Second Quarter Results on August 1, 2018

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended June 29, 2018 on Wednesday, August 1, 2018 after the market close. STAAR will host a conference call and webcast on Wednesday, August 1 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 9764509), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants.

  • How Did STAAR Surgical Company’s (NASDAQ:STAA) 1.41% ROE Fare Against The Industry?
    Simply Wall St.3 months ago

    How Did STAAR Surgical Company’s (NASDAQ:STAA) 1.41% ROE Fare Against The Industry?

    I am writing today to help inform people who are new to the stock market and looking to gauge the potential return on investment in STAAR Surgical Company (NASDAQ:STAA). STAARRead More...

  • Business Wire3 months ago

    STAAR Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreement

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, and Kobe Kanagawa Eye Clinic with locations in Tokyo and Osaka, today announced they have entered into a multi-year Strategic Cooperation Agreement to provide STAAR's EVO Visian ICL™ lenses as a primary and premium option for patients seeking visual freedom from spectacles and contact lenses through refractive eye treatment. "We are very excited that our clinic has become a strategic partner with STAAR Surgical Company and expect to introduce the ICL to many more patients," said Dr. Junki Sawai, Chairman of Kobe Kanagawa Eye Clinic.

  • Business Wire3 months ago

    STAAR Surgical Announces Resolution of FDA Warning Letter

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye announced today that it received a close-out letter from the U.S. Food and Drug Administration (FDA) on June 19, 2018 lifting a Warning Letter dated May 21, 2014. “The lifting of the Warning Letter is the result of a comprehensive remediation program that not only addressed the issues raised by the FDA in the 2014 Warning Letter, but included the assessment, remediation and upgrade of all aspects of STAAR’s quality systems to assure compliance with Quality System Regulations (QSR),” said Caren Mason, President and CEO.